 This trial is conducted in Europe. The aim of this research study is to compare the efficacy reduction in HbA1c and in blood glucose levels of insulin detemir once daily injection compared to insulin detemir twice daily injection administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use number and severity of episodes of hypoglycemia, body weight and side effects. 